Today, the Secretary of VolitionRX (NYSE: VNRX), Rodney Gerard Rootsaert, bought shares of VNRX for $9,550.
In addition to Rodney Gerard Rootsaert, one other VNRX executive reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
Currently, VolitionRX has an average volume of 27K.
Based on 3 analyst ratings, the analyst consensus is Strong Buy with an average price target of $5.67, reflecting a -69.1% downside. Starting in March 2015, VNRX received 29 Buy ratings in a row. Four different firms, including Maxim Group and Oppenheimer, currently also have a Buy rating on the stock.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
VolitionRX Ltd. is a multi-national life sciences company, which engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluid.
